Literature DB >> 27902681

Perspective: Who dares, wins.

Bibi Bielekova1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27902681      PMCID： PMC5708877          DOI： 10.1038/540S10a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  5 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  The economic cost of brain disorders in Europe.

Authors:  J Olesen; A Gustavsson; M Svensson; H-U Wittchen; B Jönsson
Journal:  Eur J Neurol       Date:  2012-01       Impact factor: 6.089

3.  Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis.

Authors:  Yen Chih Lin; Paige Winokur; Andrew Blake; Tianxia Wu; Elena Romm; Bibiana Bielekova
Journal:  Ann Clin Transl Neurol       Date:  2015-04-07       Impact factor: 4.511

4.  Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment.

Authors:  Peter Kosa; Danish Ghazali; Makoto Tanigawa; Chris Barbour; Irene Cortese; William Kelley; Blake Snyder; Joan Ohayon; Kaylan Fenton; Tanya Lehky; Tianxia Wu; Mark Greenwood; Govind Nair; Bibiana Bielekova
Journal:  Front Neurol       Date:  2016-08-15       Impact factor: 4.003

5.  Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.

Authors:  Mika Komori; Yen Chih Lin; Irene Cortese; Andrew Blake; Joan Ohayon; Jamie Cherup; Dragan Maric; Peter Kosa; Tianxia Wu; Bibiana Bielekova
Journal:  Ann Clin Transl Neurol       Date:  2016-02-01       Impact factor: 4.511
  5 in total
  2 in total

Review 1.  Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.

Authors:  Bibiana Bielekova; Michael R Pranzatelli
Journal:  Semin Pediatr Neurol       Date:  2017-08-12       Impact factor: 1.636

2.  Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.